Anticorps Tyro3 (1C11E8): sc-81160

Receptor tyrosine kinases (RTKs) represent an important class of transmembrane signaling molecules. Binding of the extracellular domain of an RTK to its cognate ligand leads to receptor dimerization and the activation of the intrinsic tyrosine kinase activity of its intracellular kinase domain. The Axl/UFO subfamily of receptor tyrosine kinases is comprised of members Tyro3 (also referred to as BYK, Brt, Dtk, RSE, Tif or Sky), Axl (also called Tyro7 or UFO) and Mer (also called Nyk, c-Eyk and Tyro12). Members of this family have a common molecular structure which contains an N-terminal extracellular domain comprised of two Ig domains, two FNIII domains and a membrane spanning single helix followed by the cytoplasmic tyrosine kinase domain. These RTKs are functionally significant in spermatogenesis, immunoregulation and phagocytosis. Tyro3, Axl and Mer are widely expressed in adult tissues with their expression most abundant in brain, testis, lymphatic and vascular tissue. Tyro3 has been shown to undergo posttranslational modifications including both tyrosine phosphorylation as well as glycosylation. Two proteins, Protein S and Gas6, have been proposed as ligands for the Axl/UFO family of receptors. Both function as anti-coagulants through an unknown mechanism. Gas6 was cloned as a growth arrest-specific gene, while Protein S is an abundant serum protein which is thought to act by indirectly inhibiting proteases involved in the coagulation response.

Alexa Fluor^® est une marque déposée de Molecular Probes Inc., OR., USA

LI-COR^® et Odyssey^® sont marques déposées de LI-COR Biosciences

Anticorps Tyro3 (1C11E8) Références:

1. Le rôle émergent de TYRO3 en tant que cible thérapeutique dans le cancer.  |  Smart, SK., et al. 2018. Cancers (Basel). 10: PMID: 30501104
2. Cibler Tyro3, Axl et MerTK (récepteurs TAM): implications pour les macrophages dans le microenvironnement tumoral.  |  Myers, KV., et al. 2019. Mol Cancer. 18: 94. PMID: 31088471
3. TYRO3 induit une résistance à la thérapie anti-PD-1/PD-L1 en limitant l'immunité innée et la ferroptose tumorale.  |  Jiang, Z., et al. 2021. J Clin Invest. 131: PMID: 33855973
4. La désactivation de TYRO3 supprime la croissance des cellules leucémiques myéloïdes.  |  Saito, T., et al. 2022. Anticancer Res. 42: 1757-1761. PMID: 35346994
5. L'agoniste TYRO3 comme thérapie pour les maladies glomérulaires.  |  Zhong, F., et al. 2023. JCI Insight. 8: PMID: 36454644
6. Régulation de l'homéostasie osseuse par MERTK et TYRO3.  |  Engelmann, J., et al. 2022. Nat Commun. 13: 7689. PMID: 36509738
7. Le blocage de TYRO3 améliore la réponse à la thérapie anti-PD-1 en modulant l'expression de CCN1 dans le microenvironnement tumoral.  |  Park, M., et al. 2023. J Immunother Cancer. 11: PMID: 36693679
8. TYRO3 protège les podocytes via la voie JNK/c-jun-P53.  |  Zhang, L., et al. 2023. Arch Biochem Biophys. 739: 109578. PMID: 36948351
9. Le ciblage du BRD3 éradique les métastases du cancer colorectal induites par le TYRO3 nucléaire.  |  Hsu, PL., et al. 2023. Sci Adv. 9: eade3422. PMID: 37043564
10. Rôle et mécanismes de Tyro3 dans la biologie des podocytes et la maladie glomérulaire.  |  Min, L., et al. 2024. Kidney Dis (Basel). 10: 398-406. PMID: 39430290

L'anticorps Tyro3 préféré est l'Anticorps Tyro3 (A-7): sc-166359.